3 results
• Allow patients to continue or start AP01 therapy for the treatment of ILD and IPF prior to regulatory approval or until the study is terminated• To evaluate safety outcomes of patients on AP01 therapy
Dose Escalation Objectives:Primary:* Determine maximum tolerated dose (MTD) and RP2DSecondary:* Establish tolerability of epcoritamab* Establish pharmacokinetic (PK) profile after single and multiple doses* Evaluate immunogenicity* Evaluate anti-…
To investigate the effect the effect of a 3-months treatment with Reslizumab on small airways function in patients with severe eosinophilic asthma, and to relate the changes in small airway function to changes in asthma symptoms and quality of life.